bioRxiv Science⌕ Search

Biology subjects

Arpat, B.

Publications and source records attributed to Arpat, B..

3 recordsLinked to original sources

Integrating knowledge, omics and AI to develop patient-specific virtual avatars

We propose a method for creating personalized regulatory networks, enabling the development of virtual avatars for cancer patients, with patient-derived xenograft (PDX) models as a test case. Starting from a Prior Knowledge Network (PKN) based on the hallmarks of cancer, we constructed gene networks that are contextualized to each sample by integrating sample-specific gene expression data. These networks were optimized using a genetic algorithm to align with individual molecular profiles, focusing on key cancer-related processes. Following network optimization, we employed Graph Convolutional Networks (GCNs) to classify samples based the structures and interactions of their individualized network models and molecular profiles. This personalized approach provides insights into drug responses and helps predict treatment outcomes, offering a path toward more targeted cancer therapies. Author summaryCancer treatment can be more effective when therapies are personalized to each patients unique molecular profile. In this study, we introduce a method to create virtual avatars of cancer patients by personalizing regulatory networks using patient-derived xenograft (PDX) models as a proof of concept. Starting from known cancer hallmarks, we developed individualized gene networks for each sample by leveraging their specific gene expression data. These networks were refined with an optimization process to match the distinct molecular characteristics of each sample. By applying advanced machine learning, specifically Graph Convolutional Networks (GCNs), we classified these personalized models to better understand likely drug responses and predict treatment outcomes. This approach brings us closer to tailoring cancer therapies to individual patients, potentially improving treatment success by targeting key cancer pathways unique to each person.

systems biology↗

Seq2scFv: a toolkit for the comprehensive analysis of display libraries from long-read sequencing platforms

Antibodies have emerged as the leading class of biotherapeutics, yet traditional screening methods face significant time and resource challenges in identifying lead candidates. Integrating highthroughput sequencing with computational approaches marks a pivotal advancement in antibody discovery, expanding the antibody space to explore. In this context, a major breakthrough has been the full-length sequencing of single-chain variable fragments (scFvs) used in in vitro display libraries. However, few tools address the task of annotating the paired heavy and light chain variable domains (VH and VL), which is the primary advantage of full-scFv sequencing. To address this methodological gap, we introduce Seq2scFv, a novel open-source toolkit designed for analyzing in vitro display libraries from long-read sequencing platforms. Seq2scFv facilitates the identification and thorough characterization of V(D)J recombination in both VH and VL regions. In addition to providing annotated scFvs, translated sequences and numbered chains, Seq2scFv enables linker inference and characterization, sequence encoding with unique identifiers and quantification of identical sequences across selection rounds, thereby simplifying enrichment identification. With its versatile and standalone functionality, we anticipate that the implementation of Seq2scFv tools in antibody discovery pipelines will efficiently expedite the full characterization of display libraries and potentially facilitate the identification of high-affinity antibody candidates.

immunology↗

Reference mouse strain assemblies for BALB/c Nude and NOD/SCID mouse models

Mouse xenograft models play a vital role in tumor studies for research as well as for screening of drugs for the pharmaceutical industry. In particular, models with compromised immunity are favorable to increase the success of transplantation, such as e.g. NOD/SCID and BALB/c Nude strains. The genomic sequence and alterations of many of these models still remain elusive and might hamper a models further optimization or proper adapted usage. This can be in respect to treatments (e.g. NOD/SCID sensitivity to radiation), experiments or analysis of derived sequencing data of such models. Here we present the genome assemblies for the NOD/SCID and BALB/c nude strains to overcome this short-coming for the future and improve our understanding of these models in the process. We highlight as well first insights into observed genomic differences for these models compared to the C57BL/6 reference genome. Genome assemblies for both are close to full chromosome representations and provided with liftover annotations from the GRCm39 reference genome.

genomics↗